AstraZeneca bets on combinations in cancer immunotherapy race

By Ben Hirschler LONDON (Reuters) - AstraZeneca is betting on drug combinations to help it catch up with industry leaders in the race to develop new treatments that harness the body's immune system to fight cancer. Bristol-Myers Squibb, Roche and Merck & Co are currently out in front with such immunotherapies, which analysts believe may extend patients' lives significantly and generate tens of billions of dollars in annual sales. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/astrazeneca-bets-combinations-cancer-immunotherapy-race-161913410--finance.html